Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
Investor Relations
Webcast ImageWebcast
Akorn, Inc. at 35th Annual J.P. Morgan Healthcare Conference (Replay)
01/09/17 at 4:30 p.m. PT
Akorn, Inc. at 35th Annual J.P. Morgan Healthcare Conference
Monday, January 9, 2017 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Akorn, Inc. at Piper Jaffray 28th Annual Healthcare Conference (Replay)
11/29/16 at 8:30 a.m. ET
Akorn, Inc. at Piper Jaffray 28th Annual Healthcare Conference
Tuesday, November 29, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Q4 2016 Akorn, Inc. Earnings Conference Call (Live)
03/01/17 at 9:00 a.m. CT
Q4 2016 Akorn, Inc. Earnings Conference Call
Wednesday, March 1, 2017 9:00 a.m. CT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Akorn, Inc. is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is an industry leader in the development, manufacturing and marketing of generic pharmaceutical products in alternate dosage forms. The Company focuses on difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

In order to successfully execute its strategy, Akorn continues to capitalize on its core strengths:

Research and development expertise in alternate dosage forms. The R&D efforts are primarily focused on the development of multisource generic products that are in dosage forms other than oral solid...  More >>

Stock Quote
AKRX (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$21.28
Change (%) Stock is Down 0.3 (1.39%)
Volume1,459,459
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Notice of Waiver to Holders - 3.50% Convertible Senior Notes due June 1, 2016
Notice of Settlement Method Election - 3.50% Convertible Senior Notes Due 2016
Recent NewsMore >>
DateTitle 
02/06/17Akorn to Report Fourth Quarter and Full Year 2016 Results
LAKE FOREST, Ill., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Wednesday, March 1, 2017 outlining the fourth quarter and full year 2016 results. In addition, the Company will host a conference call at 10:00 am ET on the same day to discuss its fourth quarter and full year 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and... 
Printer Friendly Version
12/21/16Akorn to Present at 35th Annual J.P Morgan Healthcare Conference
LAKE FOREST, Ill., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will present at the 35th Annual J.P. Morgan Healthcare Conference. Event: J.P. Morgan Healthcare Conference Date: January 9, 2017 Time: 4:30 PM PT Location: San Francisco, California The presentation will be webcast live and available on the “Events & Presentations” page in the Investor Relations section of th... 
Printer Friendly Version
12/12/16Akorn Announces Completion of FDA Re-inspection of Decatur Facility
LAKE FOREST, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted a re-inspection of its Decatur, Illinois manufacturing facility from December 5, 2016 to December 9, 2016, with no Form 483 observations.   The re-inspection was conducted to verify the implementation and effectiveness of Akorn’s responses to the observations from the June 2016 FDA inspection. ... 
Printer Friendly Version
Latest Investor PresentationMore >>
DateTitle
01/09/17January 2017 Investor Presentation Download Documentation 
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Akorn, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.